[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-374831-105":59,"doc-detail-374831-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","from-fallopian-tube-to-ovarian-cancer-understanding-the-evaluation-and-management-of-serous-tubal-intraepithelial-carcinoma-lesions","From Fallopian Tube to Ovarian Cancer - Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions","","Review article examining serous tubal intraepithelial carcinoma (STIC) as a precursor lesion for high-grade serous carcinoma (HGSC), a leading cause of mortality in gynecologic oncology. Highlights the clinical challenge due to limited data for management decisions across average-risk and high-risk patients, including BRCA mutation carriers. Discusses options such as opportunistic salpingectomy and risk-reducing salpingo-oophorectomy, recommended pathology practices, variable management after incidental detection, genetic counseling, surgery considerations, lack of chemotherapy, and surveillance uncertainty. Concludes with needs for molecular profiling, trials, and multidisciplinary care to improve prevention and outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-fallopian-tube-to-ovarian-cancer-understanding-the-evaluation-and-management-of-serous-tubal-intraepithelial-carcinoma-lesions/374831/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-fallopian-tube-to-ovarian-cancer-understanding-the-evaluation-and-management-of-serous-tubal-intraepithelial-carcinoma-lesions/374831.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is STIC considered important in high-grade serous carcinoma (HGSC)?","Question",{"text":113,"@type":114},"STIC is identified in emerging research as a precursor lesion in many HGSC cases, supporting its role in ovarian cancer pathogenesis and prevention.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the main prevention options for average-risk vs high-risk patients?",{"text":118,"@type":114},"For average-risk women, opportunistic salpingectomy during procedures like hysterectomy or cesarean section is increasingly adopted. For high-risk individuals, particularly BRCA mutation carriers, risk-reducing salpingo-oophorectomy (RRSO) is described as the gold standard.",{"name":120,"@type":111,"acceptedAnswer":121},"How is STIC managed once it is detected incidentally?",{"text":122,"@type":114},"Management varies by risk factors and lesion characteristics. Genetic counseling and testing are emphasized, surgery may be considered for STIC with microinvasive carcinoma, chemotherapy is not recommended, and surveillance is suggested despite no established monitoring guidelines.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},374831,1790474515,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Current Treatment Options in Oncology (2025) 26:910–919  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1864-025-01346-0  \nREVIEW  \nFrom Fallopian Tube to Ovarian Cancer: Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions  \nVinita Popat1 · Ernest Han1  \nAccepted: 21 July 2025 / Published online: 5 September 2025 © The Author(s) 2025  \nOpinion Statement  \nOvarian cancer, particularly high-grade serous carcinoma (HGSC), remains a leading cause of mortality in gynecologic oncology. Emerging research identifies serous tubal intraepithelial carcinoma (STIC) as a precursor lesion in many HGSC cases, highlighting its role in ovarian cancer pathogenesis and prevention. Management of STIC is challenging, as thereis only limited data available to guide clinical decision-making. For average-risk women, opportunistic salpingectomy is increasingly being adopted during routine procedures such as hysterectomy or cesarean section. This intervention has demonstrated significant potential in reducing ovarian cancer incidence while maintaining safety and feasibility. For highrisk individuals, particularly BRCA mutation carriers, risk-reducing salpingo-oophorectomy (RRSO) remains the gold standard. RRSO significantly lowers ovarian cancer risk, though alternative approaches like salpingectomy alone or radical fimbriectomy are under investigation to preserve ovarian function in younger patients. To improve STIC detection, SEEFIM pathology protocol is recommended when patients are undergoing risk-reducing surgery to prevent ovarian cancer, but challenges such as diagnostic variability and limited data persist. When STIC is detected incidentally, management varies based on risk factors and lesion characteristics. Genetic counseling and testing are essential when STIC is identified, as hereditary predisposition may guide further management. Surgical management is advised for cases of STIC with microinvasive carcinoma, but routine use of surgical management for STIC is not clearly defined in the literature. Bilateral oophorectomy is generally recommended when STIC is identified, and adnexal structures have not yet been removed. Chemotherapy is not recommended for treatment of STIC. Surveillance is suggested when STIC has been diagnosed, but there are no set guidelines as to the frequency and type of monitoring. Future directions include refining molecular profiling to predict progression and conducting randomized studies to establish evidence-based guidelines. Multidisciplinary collaboration is essential to optimize prevention and treatment, ultimately reducing HGSC incidence and improving patient outcomes.  \nKeywords STIC · Ovarian cancer · High grade serous cancer · Peritoneal cancer · BRCA · Risk reducing salpingooophorectomy  \nIntroduction  \nOvarian cancer remains one of the most formidable challenges in gynecologic oncology, characterized by significant morbidity and mortality. It has long stood as a leading cause of death among cancers arising from the female reproductive tract [1, 2]. Within this disease spectrum, high-grade serous carcinoma  \n􀀍 Vinita Popat[vpopat@coh.org](vpopat@coh.org)  \n1 Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA  \n(HGSC) represents the most common histological subtype, demonstrating particularly aggressive behavior and poor survival outcomes [3] . Survival rates beyond the ten‐year mark have remained disappointingly low at around 30%, likely due to diagnosis at advanced stages [4] . This highlights the need for enhanced approaches in both prevention and early detection. Although screening tools for ovarian cancer have been explored extensively, widespread screening is generally not recommended due to inadequate specificity and sensitivity, as  \nwell as the lack of demonstrable mortality benefit [5, 6] .  \nGiven these challenges, a critical focus has been placedon identifying individuals at increased g","cbCaijl5T37AFcAk","https://ap.wps.com/l/cbCaijl5T37AFcAk","pdf",972158,"English","# Opinion Statement\n## Background and clinical challenge\n## Prevention strategies by risk group\n## Pathology, diagnosis, and detection\n## Management after incidental detection\n## Genetic counseling and surgical considerations\n## Chemotherapy and surveillance\n## Future directions\n# Introduction\n## Epidemiology and unmet need\n## Genetic risk and prophylactic surgery\n## Tubal origin and precursor lesion spectrum","[{\"question\":\"Why is STIC considered important in high-grade serous carcinoma (HGSC)?\",\"answer\":\"STIC is identified in emerging research as a precursor lesion in many HGSC cases, supporting its role in ovarian cancer pathogenesis and prevention.\"},{\"question\":\"What are the main prevention options for average-risk vs high-risk patients?\",\"answer\":\"For average-risk women, opportunistic salpingectomy during procedures like hysterectomy or cesarean section is increasingly adopted. For high-risk individuals, particularly BRCA mutation carriers, risk-reducing salpingo-oophorectomy (RRSO) is described as the gold standard.\"},{\"question\":\"How is STIC managed once it is detected incidentally?\",\"answer\":\"Management varies by risk factors and lesion characteristics. Genetic counseling and testing are emphasized, surgery may be considered for STIC with microinvasive carcinoma, chemotherapy is not recommended, and surveillance is suggested despite no established monitoring guidelines.\"}]","From Fallopian Tube to Ovarian Cancer - Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions | PDF",1790202521,25]